Clinical Issues in Atopic Dermatitis: Debates and Discussions About Managing Moderate-to-Severe Disease

In this Clinical Issues™ program, expert faculty will review the pathophysiologic underpinnings of atopic dermatitis, best practices for comprehensive patient evaluations and the clinical profiles of systemic treatment options, including biology therapy, for patients with moderate-to-severe disease. The panel of recognized experts will translate the latest published evidence into actionable recommendations for individualized patient care. Participants are sure to leave this lively and engaging program with new information and a fresh perspective on the evolving management strategies in atopic dermatitis.

TARGET AUDIENCE

The educational design of this activity addresses the needs of allergists/clinical immunologists, dermatologists, and other clinicians who treat patients with severe atopic dermatitis.

EDUCATIONAL OBJECTIVES

Upon completion of this activity, participants will be better able to do the following:

  1. Describe the pathophysiologic mechanisms and risk factors that contribute to atopic dermatitis development and persistence, with a focus on specific targets of current and emerging systemic treatments
  2. Assess patients with atopic dermatitis over time for uncontrolled symptoms, sleep disturbances, comorbid conditions, and treatment responses
  3. Describe the mechanistic rationales and clinical evidence for current and emerging biologic therapies in the treatment of moderate-to-severe atopic dermatitis
  4. Individualize long-term therapeutic regimens for moderate-to-severe atopic dermatitis to prevent exacerbations, manage comorbidities, maximize health-related quality of life, and minimize treatment-related side effects
  5. Communicate with patients and caregivers to improve their understanding of atopic dermatitis and the importance of treatment adherence and to promote shared decision-making

FACULTY

Lisa A. Beck, MD
Dean’s Professor of Dermatology
Departments of Dermatology and Medicine
Divisions of Dermatology, Allergy/Immunology, and Rheumatology
University of Rochester Medical Center
Rochester, New York

Mark Boguniewicz, MD
Professor, Division of Pediatric Allergy-Immunology
Department of Pediatrics
National Jewish Health
University of Colorado School of Medicine
Denver, Colorado

Charles N. Ellis, MD
William B. Taylor Professor of Clinical Dermatology
Associate Chair, Department of Dermatology
University of Michigan Medical School
Ann Arbor, Michigan

Disclosure of Conflicts of Interest

It is the policy of the Elsevier Office of Continuing Medical Education that all faculty, instructors, and planners disclose any real or apparent conflicts of interest relating to the topics of this educational activity. 

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Name of Faculty or PresenterRelationship Identified With:
Lisa A. Beck, MD

Consultant/Advisor: AbbVie Inc.; AnaptysBio, Inc.; Asana BioSciences, LLC; Boehringer-Ingelheim Pharmaceuticals, Inc.; Celgene Corporation; Eli Lilly and Company; GlaxoSmithKline; Janssen Pharmaceuticals, Inc.; Novan, Inc.; Novartis Pharmaceuticals Corporation; Realm Therapeutics, Inc.; Regeneron Pharmaceuticals, Inc.; Sanofi Genzyme

Stock Ownership: Medtronic plc; Pfizer Inc.

Grant/Research Support: AbbVie Inc.; Regeneron Pharmaceuticals, Inc.
Mark Boguniewicz, MD

Consultant/Advisor: Pfizer Inc.; Regeneron Pharmaceuticals, Inc.; Sanofi Genzyme

Grant/Research Support: Regeneron Pharmaceuticals, Inc.

Speakers’ Bureau: Regeneron Pharmaceuticals, Inc.; Sanofi Genzyme
Charles N. Ellis, MD

Consultant/Advisor: AbbVie Inc.; Gilead Sciences, Inc.; GlaxoSmithKline; Medimetriks Pharmaceuticals, Inc.; Novartis Pharmaceuticals Corporation; Otsuka America Pharmaceutical, Inc.; Perrigo Company plc

Non-Faculty: Rose O’Connor, PhD, CHCP; Jim Kappler, PhD; Sandy Breslow; Alison Kemp; and Bernard M. Abrams, MD hereby state that neither they nor their spouse/life partner have had any financial relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Financial Support

This activity is supported by an independent educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals, Inc.

Provider Information

Jointly provided by the Elsevier Office of Continuing Medical Education and Integritas Communications.

CME Credit (Physicians)

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Elsevier Office of Continuing Medical Education and Integritas Communications. The Elsevier Office of Continuing Medical Education is accredited by the ACCME to provide continuing medical education for physicians.

The Elsevier Office of Continuing Medical Education designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CME Inquiries/Special Needs

For all CME inquiries or special needs, please contact elsevierCME@elsevier.com.


Disclosure of Unlabeled Use: This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The Elsevier Office of Continuing Medical Education, Integritas Communications, and Sanofi Genzyme and Regeneron Pharmaceuticals, Inc. do not recommend the use of any agent outside of the labeled indications.

Disclaimer: Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit(s)™
  • 1.00 Non-physician
Course opens: 
07/12/2018
Course expires: 
07/11/2019
Rating: 
0

Available Credit

  • 1.00 AMA PRA Category 1 Credit(s)™
  • 1.00 Non-physician

Accreditation Period

Course opens: 
07/12/2018
Course expires: 
07/11/2019
Please login or register to take this course.